跳至主要内容
临床试验/NCT07353320
NCT07353320已完成不适用

Effects of Probiotics on Alleviating Anxiety and Depression and Gut Microbiota

Wecare Probiotics Co., Ltd.0 个研究点目标入组 79 人开始时间: 2024年4月10日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
79

研究概览

简要总结

This study is a randomized, double-blind, placebo-controlled trial aimed primarily at investigating the effects of Weizmannia coagulans BC99 on alleviating anxiety and depression and the gut microbiota.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged 18-65 years.
  • Individuals experiencing scientific research, employment-related, or occupational stress, including graduate students or community-dwelling adults with job-related pressure.
  • A Hamilton Depression Rating Scale (HAMD-17) score ≥ 8 and/or a Hamilton 4) Anxiety Rating Scale (HAMA-14) score ≥ 7 at screening.
  • Ability and willingness to voluntarily participate in the study and to provide written informed consent prior to enrollment.

排除标准

  • A confirmed previous diagnosis of other psychiatric disorders, including intellectual disability, bipolar disorder, treatment-resistant depression, or suicidal ideation.
  • Pregnant or breastfeeding women.
  • Individuals with known food or drug allergies, or those with alcohol abuse or psychotropic substance abuse.
  • Use of antibiotics or probiotics known to affect gut microbiota for more than one week within one month prior to enrollment.
  • Participants who withdrew from the study, discontinued intervention, or were unable to complete the study for any reason.

研究者

申办方类型
Industry
责任方
Sponsor

相似试验